跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2017-000800-59-IT
EUCTR2017-000800-59-IT进行中（未招募）1 期

A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) - LIBRETTO-001

oxo Oncology, Inc.0 个研究点目标入组 970 人开始时间: 2020年2月7日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
1 期
状态
进行中（未招募）
发起方
入组人数
970
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1.Patients with a locally advanced or metastatic solid tumor who:
  • •have progressed on or are intolerant to standard therapy, or
  • •no standard therapy exists, or in the opinion of the Investigator, are not candidates for or would be unlikely to tolerate or derive significant clinical benefit from standard therapy, or
  • •decline standard therapy.
  • •2.Prior MKIs with anti-RET activity are allowed.
  • •3.A RET gene alteration is not required initially. Once adequate PK exposure is achieved, evidence of RET gene alteration in tumor and/or blood is required
  • •4.Measurable or non-measurable disease as determined by RECIST 1.1 or RANO as appropriate to tumor type.
  • •5.At least 18 years of age.
  • •For countries and sites where approved, patients as young as 12 years of age may be enrolled.
  • •6.Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 (age = 16 years) or Lansky Performance Score (LPS) = 40% (age < 16 years) with no sudden deterioration 2 weeks prior to the first dose of study treatment.
  • •7.Life expectancy of at least 3 months.
  • •8.Archived tumor tissue sample available.
  • •9.Adequate hematologic status, defined as:
  • •Absolute neutrophil count (ANC) = 1.0.10^9/L not requiring growth factor support for at least 7 days prior to treatment, and
  • •Platelet count = 75.10^9/L not requiring transfusion support for at least 7 days prior to treatment, and
  • •Hb = 9 g/dL not requiring transfusion support or erythropoietin for at least 7 days prior to treatment.
  • •10.Adequate hepatic function, defined as:
  • •ALT and AST = 2.5 ULN or = 5 ULN with documented liver involvement (such as liver metastasis or a primary biliary tumor); and
  • •Total bilirubin = 1.5 ULN or = 3 ULN with documented liver involvement (patients with Gilbert’s Disease may be enrolled with prior Sponsor approval).
  • •11.Adequate renal function, with estimated glomerular filtration rate = 30 mL/minute (up to 6 patients with an estimated glomerular filtration rate (eGFR) = 15 and < 30 will be allowed to enroll with Sponsor approval).
  • •12.Ability to swallow capsules and comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation. If the liquid formulation is widely available the requirement may be waived with Sponsor approval.
  • •13.Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following the last dose of study treatment; this may include barrier methods such as condoms or diaphragms with spermicidal gel.
  • •As for phase 1 with the following modifications:
  • •1.Cohorts 1 and 3: failed or intolerant to standard of care. Cohorts 2 and 4 without prior standard first line therapy.
  • •2.Cohorts 1-4: enrollment will be restricted to patients with evidence of a RET gene alteration in tumor (i.e., not just blood) as defined in Table 3 3. However, a positive germline DNA test for a RET gene mutation as defined in Table 3 3 is acceptable in the absence of tumor tissue testing for patients with MTC.
  • •3.Cohorts 1-4: at least one measurable lesion as defined by RECIST 1.1 or RANO, as appropriate to tumor type and not previously irradiated (unless PD for the irradiated lesion[s] has been radiographically documented).
  • •4.Cohort 4: radiographic PD within the previous 14 months.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 87
  • •F.1.2 Adults (18-64 years) yes

排除标准

  • •1.Phase 2 Cohorts 1-4: an additional validated oncogenic driver that could cause resistance to LOXO-292 treatment. See Appendix C (Table 11 3) for examples.
  • •2.Cohorts 1 to 5: Prior treatment with a selective RET inhibitor(s) (including investigational selective RET inhibitor[s]).
  • •3.Investigational agent or anticancer therapy (including chemotherapy, biologic therapy, immunotherapy, anticancer Chinese medicine or other anticancer herbal remedy) within 5 half-lives or 2 weeks (whichever is shorter) prior to planned start of LOXO 292. In addition, no concurrent investigational anti-cancer therapy is permitted.
  • •4.Major surgery (excluding placement of vascular access) within 4 weeks prior to planned start of LOXO 292.
  • •5.Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment, with the exception of patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation, which must be completed at least 4 weeks prior to the first dose of study treatment.
  • •6.Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.
  • •7.Symptomatic primary CNS tumor, metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression.
  • •Patients are eligible if neurological symptoms and CNS imaging are stable and steroid dose is stable for 14 days prior to the first dose of LOXO-292 and no CNS surgery or radiation has been performed for 28 days, 14 days if stereotactic radiosurgery (SRS).
  • •8.Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of LOXO 292 or prolongation of the QT interval corrected for heart rate using Fridericia’s formula (QTcF) interval > 470 msec during Screening. Correction of suspected drug-induced QTcF prolongation may be attempted at the Investigator’s discretion if clinically safe to do so.
  • •9.Active uncontrolled systemic bacterial, viral, or fungal infection or serious ongoing intercurrent illness, such as hypertension or diabetes, despite optimal treatment. Screening for chronic conditions is not required.
  • •10.Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug.
  • •11.Uncontrolled symptomatic hyperthyroidism or hypothyroidism.
  • •12.Uncontrolled symptomatic hypercalcemia or hypocalcemia.
  • •13.Current treatment with certain strong CYP3A4 inhibitors or inducers and certain prohibited concomitant medications.
  • •14.Current treatment with PPIs (refer to Appendix E).
  • •15.Pregnancy or lactation.
  • •16.Active second malignancy other than minor treatment of indolent cancers.

研究者

发起方
oxo Oncology, Inc.

相似试验

进行中（未招募）
1 期
A Phase 1/2 study on the effects of LOXO-292 (study drug) in patients with advanced solid tumorsMale or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or bloodMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2017-000800-59-GBoxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company1,070
撤回
2 期
A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)
NL-OMON48590oxo Oncology, Inc.3
进行中（未招募）
1 期
A Phase 1 study on the effects of LOXO-292 (study drug) in patients with advanced solid tumorsDose escalation: Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor refractory to standard of care therapy, or for whom no standard of care therapy is available.Dose expansion: Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.MedDRA version: 20.0Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2017-000800-59-NLoxo Oncology, Inc.570
招募中
1 期
A PHASE 1/2 STUDY OF ORAL LOXO-292 IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING RET-FUSION NON-SMALL CELL LUNG CANCER, MEDULLARY THYROID CANCER, AND OTHER TUMORS WITH INCREASED RET ACTIVITYAdvanced Solid Tumors, Including RET-Fusion Non Small Cell Lung Cancer, Medullary Thyroid Cancer, an
JPRN-jRCT2051220060Hokonohara Toshihiro25
进行中（未招募）
1 期
An Early Phase Study with the Drug LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)MedDRA version: 20.1 Level: LLT Classification code 10008976 Term: Chronic lymphocytic leukemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10003908 Term: B-cell small lymphocytic lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10029547 Term: Non-Hodgkin's lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-003340-24-FRoxo Oncology, Inc.190